Article

The costs associated with treating spine-related conditions are enormous and are
trending upward. Current methods employed to treat inflammatory-mediated pain are
targeted at alleviating symptoms, rather than correcting the underlying cause of
disease. It is clear that a biochemical basis for inflammatory-mediated
intervertebral disk, facet joint, and nerve pain exists. Biologic therapies that
address the underlying cause of pain could potentially decrease the costs
associated with treating spine pathology. MMPs, IL-1, TNF- alpha, IL-6, NGF,
bradykinin, prostaglandins, and nitric oxide are implicated in much of the
catabolic effects seen in the pathogenesis of inflammatory-mediated pain and are
good targets for inhibition. The anticatabolic and anabolic effects of TIMPs, BMPs, TGF- beta, and IGF-1 are targets already shown to favorably impact disk
matrix homeostasis. With rapid advances in biomedical technology, these
interventions may be available for clinical use in the near future.
CI - Copyright (c) 2011 American Academy of Physical Medicine and Rehabilitation.
Published by Elsevier Inc. All rights reserved.

Langue : ANGLAIS